ロード中...
An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma
The 5-year survival rate of patients with B cell lymphoma is about 50% after initial diagnosis, mainly because of resistance to chemotherapy. Hence, it is necessary to understand the mechanism of chemo-resistance and to explore novel methods to circumvent multidrug resistance. Previously, we showed...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6737009/ https://ncbi.nlm.nih.gov/pubmed/31555598 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00861 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|